Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)
Conditions
Interventions
Etigilimab
Nivolumab
Locations
16
United States
Mereo Investigator Site
Phoenix, Arizona, United States
Mereo Investigator Site
Greenbrae, California, United States
Mereo Investigator Site
Los Angeles, California, United States
Mereo Investigator Site
Jacksonville, Florida, United States
Mereo Investigator Site
Boston, Massachusetts, United States
Mereo Investigator Site
Ann Arbor, Michigan, United States
Start Date
March 23, 2021
Primary Completion Date
October 30, 2023
Completion Date
October 30, 2023
Last Updated
March 17, 2025
NCT05720117
NCT06898450
NCT05223608
NCT06625775
NCT05098132
NCT05719558
Lead Sponsor
Mereo BioPharma
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions